GlassScriptPhysician profile
Madeline Munn
NPI 1174957476
$1,895.07
in general payments reported to CMS, 2019-2025
20 companies · $1,460 in 2025
The $1,460 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.80 · 2022: $94.62 · 2023: $284 · 2025: $1,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,744.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $446.79 | 2022-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $319.67 | 2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $212.46 | 2023-2025 | Freestyle Libre 3 |
| Sequel Med Tech, LLC | $169.85 | 2025 | Twiist |
| Dexcom, INC. | $150.47 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Amgen INC. | $78.99 | 2025 | Tepezza, Prolia, Evenity |
| Xeris Pharmaceuticals, INC. | $75.33 | 2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.78 | 2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $52.70 | 2025 | |
| Currax Pharmaceuticals LLC | $50.79 | 2021-2022 | |
| Corcept Therapeutics | $45.46 | 2025 | Korlym |
| Beta Bionics, INC. | $42.01 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amneal Pharmaceuticals LLC | $38.30 | 2025 | Unithroid |
| Redhill Biopharma INC. | $24.70 | 2022 | |
| Insulet Corporation | $24.33 | 2025 | Omnipod |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $23.43 | 2025 | Jubbonti |
| Endo Pharmaceuticals INC. | $22.00 | 2021 | |
| Neurocrine Biosciences, INC. | $21.35 | 2025 | |
| Ascendis Pharma Endocrinology INC | $17.80 | 2025 | Yorvipath |
| Abbvie INC. | $13.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeline Munn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.